John JD - Insulet Senior Counsel
| PODD Stock | USD 262.00 4.58 1.72% |
Executive
John JD is Senior Counsel of Insulet
| Age | 64 |
| Address | 100 Nagog Park, Acton, MA, United States, 01720 |
| Phone | 978 600 7000 |
| Web | https://www.insulet.com |
Insulet Management Efficiency
The company has return on total asset (ROA) of 0.0757 % which means that it generated a profit of $0.0757 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4879 %, meaning that it created $0.4879 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.09. The current year's Return On Capital Employed is expected to grow to 0.11. At present, Insulet's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Intangibles To Total Assets are forecasted to decline to 0.06.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Shelly Selvaraj | DexCom Inc | 65 | |
| Kathy Sherwood | Inspire Medical Systems | N/A | |
| Melissa Mann | Inspire Medical Systems | N/A | |
| Arnold Pinkston | Edwards Lifesciences Corp | 65 | |
| Shirley Stacy | Align Technology | N/A | |
| Michael McBreen | Integra LifeSciences Holdings | 57 | |
| Mike Panos | Stryker | N/A | |
| MPH MD | Inari Medical | N/A | |
| Julie JD | Align Technology | 56 | |
| Michael Brown | DexCom Inc | 54 | |
| Alon Yaari | InMode | N/A | |
| Jennifer OlsonWilk | Align Technology | 46 | |
| Jason Mills | Penumbra | N/A | |
| Scott Leinenweber | Abbott Laboratories | 52 | |
| Daniel Lippis | Edwards Lifesciences Corp | 48 | |
| Ruth Fleming | Integra LifeSciences Holdings | N/A | |
| Laurene Isip | Integra LifeSciences Holdings | N/A | |
| Paul Hataishi | Masimo | 49 | |
| Arnold JD | Edwards Lifesciences Corp | 65 | |
| Mathieu Aussermeier | Integra LifeSciences Holdings | N/A | |
| Dirksen Lehman | Edwards Lifesciences Corp | N/A | |
Management Performance
| Return On Equity | 0.49 | ||||
| Return On Asset | 0.0757 |
Insulet Leadership Team
Elected by the shareholders, the Insulet's board of directors comprises two types of representatives: Insulet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insulet. The board's role is to monitor Insulet's management team and ensure that shareholders' interests are well served. Insulet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insulet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Benjamin, Senior Vice President R&D, New Product Development and Commercialization | ||
| Philip Hildale, Senior Care | ||
| Mark Field, Senior CTO | ||
| Prem Singh, Senior Operations | ||
| Laetitia Cousin, Quality Affairs | ||
| John JD, Senior Counsel | ||
| John Kapples, Senior Vice President General Counsel, Secretary | ||
| Wayde McMillan, CFO, Executive Vice President | ||
| Angela Wiczek, Senior Communications | ||
| Charles Alpuche, Senior Vice President Global Manufacturing and Operations | ||
| Lauren Budden, Chief VP | ||
| Michael Spears, Senior Vice President Quality, Regulatory, and Clinical Affairs | ||
| James Hollingshead, CEO President | ||
| Bret Christensen, Chief Commercial Officer | ||
| Ana Chadwick, CFO VP | ||
| Deborah CPA, Vice Relations | ||
| Shacey Petrovic, Chief Commercial Officer |
Insulet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insulet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.49 | ||||
| Return On Asset | 0.0757 | ||||
| Profit Margin | 0.21 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 18.87 B | ||||
| Shares Outstanding | 70.14 M | ||||
| Shares Owned By Insiders | 0.34 % | ||||
| Shares Owned By Institutions | 99.66 % | ||||
| Number Of Shares Shorted | 2.84 M | ||||
| Price To Book | 16.44 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.46 | Earnings Share 5.87 | Revenue Per Share 28.341 | Quarterly Revenue Growth 0.257 | Return On Assets 0.0757 |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.